- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05905185
Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity
The goal of this clinical trial is to investigate the effects of tocotrienol-rich fraction vitamin E supplementation on liver enzymes in overweight and obese children with non-alcoholic fatty liver disease as compared to placebo.
The main question[s] it aims to answer are:
- Does supplementation of tocotrienol-rich fraction vitamin E reduce the level of liver enzymes and improve liver steatosis in non-alcoholic fatty liver disease among overweight and obese children?
- Does tocotrienol-rich fraction vitamin E supplementation improve the level of liver steatosis by reducing the level of DNA damage?
Participants will :
- consume daily either a dose of 50 mg of tocotrienol-rich fraction (TRF) vitamin E or a placebo for 6 months.
- Routine clinical assessments include weight, height, waist circumference, and BMI. Fasting glucose, and fasting serum lipid.
- The following investigations were performed upon recruitment and following 6 months of intervention: (i) liver biomarker and enzymes; (ii) DNA damage; (iii) TNFα, IL-6 and IFN-gamma genes; (iv) Fibroscan.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Methodology This study enrolled a diverse group of participants aged 10 to 18, regardless of gender, who were diagnosed with fatty liver disease detected via ultrasonography and abnormally high alanine transaminase levels (at least two-fold higher than the upper limits for their respective genders). The trial consisted of 29 patients, with 15 receiving a daily oral dose of 50 mg TRF and 14 receiving a placebo for a duration of six months. Various clinical parameters, LIVERFASt in vitro diagnostic test, fibroscan, biochemical parameters, DNA damage, and gene expression, both at the outset and at the end of the study were monitored.
The amount of blood sample taken was 13mls each at entry and on completion at 6 months. Details of these tests are as shown below:
Transient Elastography (FibroScan):
This is a non-invasive test to measure liver stiffness, kPa (indicator of liver fibrosis) and to detect degree of fat accumulation (CAP range value of 100-400 dB/m), liver stiffness of > 8kPa indicates advanced fibrosis while CAP of > 263 indicates fatty liver. During the screening, the participant lied down on the examination bed with his/her right hand behind his/her head. A probe was placed by the investigator between the right ribs of the patient. Measurements were recorded into the machine (FibroScan® 502 Touch). The screening is quick and easy, usually taking less than 15 minutes. The scanned steatosis was scored and graded.
Determination of DNA Damage The DNA Damage pre and post intervention were conducted by using CometAssay Kit (Trevigen, Gaithersburg, USA) following the manufacturer's protocol. Briefly, blood cells in 5 μL medium was suspended in 70 μL warm 0.6% low-melting point (LMA) agarose (Boehringer Mannheim, Germany) (DNAse-free, RNAsefree). Slides were allowed to sit in the alkaline buffer for 20 min to allow unwinding of DNA strands and expression of alkali-labile damage. Electrophoresis was performed for 20 min at 300 mA and 25 V. Following dropwise neutralization (TrisHCl, pH 7.5) for 5 min, cells were stained by applying 30 μL 1X ethidium bromide. The slides were examined and the tail length was measured with a fluorescence microscope (Carl Zeiss, Germany). The DNA migration of 100 randomly selected cells were examined for each sample. A total damage score was determined by multiplying the number of cells assigned to each grade of damage by the numeric value of the grade according to methods described by Heaton et al. [19]. Total DNA damage score was calculated as follows. Total DNA damage = [(0 × n0) + (1 × n1) + (2 × n2) + (3 × n3) + (4 × n4)] where n0 =cells with Score 0, n1 = cells with Score 1, n2 = cells with Score 2, n3 = cells with Score 3, and n4 = cells with Score 4.
Determination of liver biomarker and enzyme The levels of liver enzymes including alanine aminotransferase, ALT, aspartate aminotransferase, AST, gamma glutamyl transferase, GGT, and alkaline phosphatase, ALP, pre and post intervention were determined from the blood samples of the patients. Other biomarkers such as lipid profile, α-2 macroglobulin and haptoglobin were also be analysed. The blood samples were collected in a BD Vacutainer and centrifuge at 1500 xg for 15 mins for the serum separation. The serum was stored in -80°C if it is not processed immediately. The levels of the liver enzymes were determined by using ADVIA 1800 (Siemens, USA).
Quantitative Polymerase Chain Reaction (qPCR):
Total RNA was extracted from blood samples of NAFLD patients with or without tocotrienol. Primers and probes for TNFα, IL-6 and IFN-gamma genes were designed. 1 ug/ul of total RNA was converted to cDNA which then be used for PCR reaction. All samples were analysed in duplicate. Expression of genes was determined after normalised with the housekeeping genes.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Kuala Lumpur, Malaysia
- National University of Malaysia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children aged 13 - 18 years old
- Overweight or obese (BMI percentile range ≥ 85%)
- Able to swallow small oral soft gel capsule
- Diagnosis of NAFLD confirmed by presence of fatty liver detected by abdominal ultrasound and controlled attenuation parameter (CAP) score of >263
- Elevated alanine transaminase (ALT) ≥ 2 fold upper limits (26 U/L for boys and 22 U/L for girls)
Exclusion Criteria:
- Evidence of other primary chronic liver diseases (as determined by clinical and standard investigations) - e.g. Hepatitis B, C infections, autoimmune hepatic disorders.
- Not on any dietary supplements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Sime Darby Bioganic Sdn.
Bhd, Malaysia provided the TRF pills that were used in the study.
The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
During a period of six months, the patients were instructed to consume oral TRF (50 mg) daily
|
The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
|
Placebo Comparator: Placebo
During a period of six months, the patients were instructed to consume oral placebo (50 mg) pills daily.
|
50mg of Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean difference of fibrosis score, inflammation (activity) score and steatosis score
Time Frame: Six months
|
Serum LiverFASt level is a blood test to detect the degree and stage of: fibrosis (0-1), inflammation (0-1), and steatosis (0-1) scores.
The higher the score indicates the higher the degree of fibrosis, inflammation and steatosis.
These measurements were taken at the baseline and at the end of trial.
|
Six months
|
Mean difference of fasting blood glucose
Time Frame: 6 months
|
Fasting blood glucose levels were measured at the baseline and at the end of trial
|
6 months
|
Mean difference in aspartate aminotransferase & alanine aminotransferase levels
Time Frame: 6 months
|
Aspartate aminotransferase & alanine aminotransferase levels were measured at the baseline and at the end of trial.
|
6 months
|
Mean difference in apolipoprotein-A1, triglycerides, total cholesterol levels
Time Frame: 6 months
|
Total cholesterol, triglycerides, apolipoprotein-A1 levels were measured at the baseline and at the end of trial
|
6 months
|
Mean difference of liver steatosis and liver stiffness, measured by controlled attenuation parameter (CAP) score in percentage and kPa respectively, by transient elastography
Time Frame: 6 months
|
Transient elastography was performed to measure controlled attenuation parameter (%) and liver stiffness (kPa) at the baseline and at the end of trial
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean difference in tail length to represent DNA damage
Time Frame: 6 months
|
Determination of DNA damage using comet assay was done at the baseline and at the end of trial
|
6 months
|
Mean difference in the interleukin-6, TNF-alpha and interferon-gamma
Time Frame: 6 months
|
IL-6, TNF-alpha and interferon-gamma levels were measured at the baseline and at the end of trial
|
6 months
|
Mean difference in the body mass index (percentile)
Time Frame: 6 months
|
Weight measurement based on age was measured at the baseline and at the end of trial
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Norfilza Mohd Mokhtar, National University of Malaysia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Liver Diseases
- Obesity
- Fatty Liver
- Pediatric Obesity
- Non-alcoholic Fatty Liver Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Vitamin E
- Tocopherols
- Tocotrienols
Other Study ID Numbers
- GUP 2018-052
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Tocotrienol-rich fraction vitamin E (TRF)
-
Wayne State UniversityUniversiti Putra Malaysia; National Kidney Foundation; Ministry of Health, Malaysia and other collaboratorsCompletedEnd Stage Renal Disease | Chronic Kidney DiseaseUnited States
-
Nur Aishah Mohd TaibMalaysia Palm Oil BoardUnknownBreast Cancer FemaleMalaysia
-
Malaysia Palm Oil BoardUniversity of MalayaCompleted
-
Malaysia Palm Oil BoardCompleted
-
Universidade Federal FluminenseWayne State UniversityCompletedInflammation | Chronic Kidney Diseases | Hemodialysis | Oxidative Stress | MicrobiotaBrazil
-
Malaysia Palm Oil BoardUniversiti Putra MalaysiaCompletedMetabolic Syndrome | Platelet Aggregation, SpontaneousMalaysia
-
University of California, Los AngelesWithdrawnCholesterol LoweringUnited States
-
Malaysia Palm Oil BoardUniversiti Putra MalaysiaUnknownInflammation | Cardiovascular Risk FactorMalaysia
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI); BioGene Life ScienceCompleted